P2RY12 and atrial fibrillation: Based on the results of RE-DUAL PCI [2], PIONEER-AF [3], AUGUSTUS [4], and ENTRUST-AF PCI [5] studies, and on two recent meta-analyses [27,28], a dual-pathway antithrombotic therapy (DAT) using a single antiplatelet agent (a P2Y12 inhibitor) is now recommended in most AF patients early after PCI.